TY - JOUR
T1 - Technical details and outcomes of peroral endoscopic myotomy with fundoplication
T2 - the first U.S. experience (with video)
AU - Shrigiriwar, Apurva
AU - Zhang, Linda Y.
AU - Ghandour, Bachir
AU - Bejjani, Michael
AU - Mony, Shruti
AU - Bapaye, Amol
AU - Khashab, Mouen A.
N1 - Publisher Copyright:
© 2023 American Society for Gastrointestinal Endoscopy
PY - 2023/3
Y1 - 2023/3
N2 - Background and Aims: Peroral endoscopic myotomy (POEM) is an established endoscopic treatment for achalasia; however, post-POEM rates of GERD remain a significant cause of concern. Single-session POEM with fundoplication (POEM-F) to treat achalasia was recently described to reduce post-POEM GERD. This study aims to report the technical feasibility, safety, and early outcomes of the first U.S. cohort of POEM-F. Methods: We retrospectively reviewed all patients with achalasia treated with POEM-F at our center. The primary endpoint was technical success, defined as the successful completion of all steps of the POEM-F procedure. Results: Six patients (mean age, 50 ± 4.8 years; 1 woman) underwent POEM-F for achalasia. Technical success was achieved in all patients (6/6), and no major immediate or delayed (up to 30 days postprocedure) adverse events were seen. At the 1-month follow-up visit, the mean Eckardt score decreased from 8.8 ± 1.1 to .3 ± .5. The GERD health-related quality of life and reflux symptom index scores obtained at the 1-month follow-up, with patients on proton pump inhibitors, were 2.3 ± 3.7 and 2.2 ± 2.5, respectively. Conclusions: This first case series on POEM-F in the United States suggests that POEM-F is feasible and safe with excellent short-term outcomes.
AB - Background and Aims: Peroral endoscopic myotomy (POEM) is an established endoscopic treatment for achalasia; however, post-POEM rates of GERD remain a significant cause of concern. Single-session POEM with fundoplication (POEM-F) to treat achalasia was recently described to reduce post-POEM GERD. This study aims to report the technical feasibility, safety, and early outcomes of the first U.S. cohort of POEM-F. Methods: We retrospectively reviewed all patients with achalasia treated with POEM-F at our center. The primary endpoint was technical success, defined as the successful completion of all steps of the POEM-F procedure. Results: Six patients (mean age, 50 ± 4.8 years; 1 woman) underwent POEM-F for achalasia. Technical success was achieved in all patients (6/6), and no major immediate or delayed (up to 30 days postprocedure) adverse events were seen. At the 1-month follow-up visit, the mean Eckardt score decreased from 8.8 ± 1.1 to .3 ± .5. The GERD health-related quality of life and reflux symptom index scores obtained at the 1-month follow-up, with patients on proton pump inhibitors, were 2.3 ± 3.7 and 2.2 ± 2.5, respectively. Conclusions: This first case series on POEM-F in the United States suggests that POEM-F is feasible and safe with excellent short-term outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85147105697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147105697&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2022.10.027
DO - 10.1016/j.gie.2022.10.027
M3 - Article
C2 - 36265528
AN - SCOPUS:85147105697
SN - 0016-5107
VL - 97
SP - 585
EP - 593
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 3
ER -